Case Report

Dedifferentiated Paratesticular Liposarcoma with Osseous Metaplasia

Kostas Chondros,1 Ioannis Heretis,1 Michael Papadakis,2 Vasiliki Bozionelou,3 Emmanouil Mavromanolakis,1 Nikolaos Chondros,1 and Charalampos Mamoulakis 1

1Department of Urology, University General Hospital of Heraklion, University of Crete Medical School, Heraklion, 71110 Crete, Greece
2Department of Pathology, University General Hospital of Heraklion, University of Crete Medical School, Heraklion, 71110 Crete, Greece
3Department of Medical Oncology, University General Hospital of Heraklion, University of Crete Medical School, Heraklion, 71110 Crete, Greece

Correspondence should be addressed to Charalampos Mamoulakis; c.mamoulakis@med.uoc.gr

Received 25 February 2015; Accepted 7 April 2015

Copyright © 2015 Kostas Chondros et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Paratesticular liposarcoma is a rare tumour of the genitourinary track but the most common of all sarcomas in adults. The dedifferentiated variation occurs only in 10% of liposarcoma cases. The typical clinical presentation is similar to an inguinal hernia or a benign lipoma. We present the case of a dedifferentiated paratesticular liposarcoma with osseous metaplasia of the spermatic cord, in a male presented with acute scrotum.

1. Introduction

Liposarcoma is a malignant neoplasm of the adipose tissue representing the second most common type of sarcoma following malignant fibrous histiocytoma (20% of the cases) [1]. It is the most common type of genitourinary sarcomas in adults, and it is usually located in the spermatic cord, epididymis, or testis. Histologic classification has been well established by the World Health Organization (WHO 2013) and includes four different subtypes of liposarcoma among which the well-differentiated liposarcoma (WDL) represents the largest subgroup (40–45%) [2]. Cell dedifferentiation, as a pathological process, confers a poorer prognosis and occurs in up to 10% of WDL. Different pathological components such as leiomyosarcomatous differentiation, osteosarcomatous differentiation, and bone formation have been described in case reports with a potential role in the overall prognosis [3–6]. The clinical presentation of genitourinary liposarcomas is that of a painless, palpable large unilateral scrotal or inguinal mass. A differential diagnostic problem emerges due to similar symptomatology with inguinal hernias or subcutaneous lipomas. Radiological evaluation is helpful for the diagnosis. Other clinical presentations, such as acute scrotum, are rather rare and an immediate surgical exploration is required.

2. Case Presentation

A 61-year-old male presented to the emergency department with acute right inguinal pain with concomitant ipsilateral scrotal swelling over the past 24 hours. Clinical examination revealed a painful solid mass on the right spermatic cord and normal testicles. The patient was afebrile, without any lower urinary tract symptoms or signs of urinary infection. Laboratory investigation was normal including testicular tumor markers (serum levels of α-fetoprotein (AFP), human chorionic gonadotropin (hCG), and lactate dehydrogenase (LDH)) within normal limits. Radiological evaluation included scrotal ultrasonography (US) and computed tomography (CT) scan. US scan revealed a right-sided solid paratesticular mass with normal testes (Figure 1). The CT scan documented the presence of a solid soft-tissue mass 3.6 × 3.7 × 5.8 cm originating from the right spermatic cord and a small calcification...
inside the inguinal canal. Retroperitoneal and pelvic lymph nodes were within normal limits (Figures 2 and 3).

Due to the progressive severe hemiscrotal pain the patient was submitted to an emergency diagnostic scrotal exploration and surgical removal of the mass. The pathological investigation revealed a variably anaplastic spindle cell neoplasm with prominent and inflamed collagenous stroma and a high degree of cellular atypia. Immunohistochemical markers of the tumor were as follows: S-100 (−), HHF-35 (−), vimentin (+), C-kit (−), desmin (+), SMA (+), and CD 34 (+). Cytogenetic evaluation in substains showed strong and diffuse nuclear positivity for murine double minute 2 (MDM2) and cyclin-dependent kinase-4 (CDK4) consistent with translocation of these genes on the long arm of chromosome 12. These findings were suggestive of a low grade dedifferentiated liposarcoma (DDL) (Figure 4). A supplementary radical orchietomy with high ligation of the spermatic cord was immediately performed due to positive surgical margins. In the second surgical specimen, mature bone formation within the spermatic cord was detected due to osseous metaplasia of the actual neoplasm (Figure 5). Surgical margins were confirmed this time to be negative and the testicle showed mild atrophy without any other significant anomalies.

Due to high comorbidity (coronary artery disease, history of myocardial infarction with angioplasty and stent placement, and hypertension), the patient was not submitted to adjuvant chemotherapy as decided in our multidisciplinary tumor board. Additionally, the option of local radiotherapy was not considered beneficial. Therefore an intensive follow-up schedule was applied, with chest/abdomen CT scans every 3 months for the first year and every 6 months for the second year. Two years after the initial diagnosis there is no local or systematic recurrence.

3. Discussion

Liposarcomas are classified according to WHO classification of soft-tissue tumors (2013) in four major subtypes: atypical lipomatous tumor/WDL, DDL, myxoid liposarcoma, and pleomorphic liposarcoma [2]. Histological type has been showed in several studies to be an important prognostic factor for the recurrence and disease-specific mortality [4–7]. Dedifferentiation is detected in up to 10% of WDL of any subtype and it is related to poorer prognosis. However, it presents less aggressive clinical behavior compared to other high grade pleomorphic sarcomas [8]. Histopathologically, there are two grades (low and high) of DDL. Low grade dedifferentiation is characterized most often by the presence...
optimally, radical resection with negative margins is concerned the data are limited. The trend is that adjuvant therapy confers survival benefit. As far as paratesticular liposarcoma, that the administration of adjuvant radiotherapy did not seem to result in beneficial outcomes for the patients. Other studies reported that the administration of adjuvant radiotherapy did not seem to confer survival benefit. As far as paratesticular liposarcoma is concerned the data are limited. The trend is that adjuvant radiotherapy should be used in patients with positive surgical margins or when the adequacy of local excision is in doubt. In these cases there is a decrease in local recurrence up to 44% but there is no impact on the overall survival rate at 5 years [14]. Definitive radiation therapy is recommended for patients who are not surgical candidates, with radiation doses ranging from 60 to 70 Gy.

Systemic chemotherapy should be given to patients with evidence of retroperitoneal or distant metastases. A variety of chemotherapeutic agents and combinations are available based mainly on doxorubicin, ifosfamide, mesna, and dacarbazine [15]. Limited data are available for adjuvant chemotherapy in paratesticular liposarcoma. Age, performance status, size, grade, location, type of initial surgery, and margin status should be taken into account when there is a consideration for adjuvant therapy. Combination chemotherapy regimens with concurrent radiation therapy have higher response and prohibitive toxicities and therefore should only be applied in selected patients [16].

There are several survival rates reported, depending on the histologic subtype, grade, size, surgical margins status, and the primary site of liposarcomas. Five-year survival rates of paratesticular liposarcomas range from 20% to 80% while the long-term survival of men with all paratesticular sarcomas is approximately 50%. Dedifferentiation is mainly considered to be a poor prognostic factor especially for local recurrence whereas well-differentiated recurrences may be noted. Low grade is not a prognostic factor in these types and metastatic risk is up to 20% [17].

An intensive follow-up schedule is worthwhile for these patients. Radiologic evaluation with CT or MRI is highly recommended at least every 3–6 months for the first 3 years and annually thereafter [15].

In our case, the patient had a low grade paratesticular DDL that was surgically excised with negative surgical margins. The osseous metaplasia was not considered to confer any aggressiveness to the tumor. The radiologic evaluation was negative for lymph node disease or distant metastasis. The patient had significant comorbidities and medium performance status and thus no adjuvant therapy was applied.

4. Conclusion
Paratesticular liposarcoma requires aggressive surgical approach for curative treatment with radical orchiectomy. The dedifferentiated subtype is less common with a trend to recur locally. Osseous metaplasia is rare and does not represent an unfavorable prognostic factor. However, these tumors, due to their potential metastatic risk, should be treated with radical orchiectomy followed by additional therapy in cases of local recurrence or distant metastases and the patients should undergo intensive radiologic follow-up.

Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
Acknowledgments

The authors would like to thank Professor Christopher D. Fletcher (Department of Pathology, Harvard Medical School, Boston, US) for his contribution to the diagnosis of the surgical specimen. Mrs. D. Pantartzi, Scientific Secretary of the Clinical Trial Office at the Department of Urology, University of Crete Medical School, is gratefully acknowledged for the administrative and technical support.

References

[1] A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA: A Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008.
[2] V. Y. Jo and C. D. M. Fletcher, “WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition,” Pathology, vol. 46, no. 2, pp. 95–104, 2014.
[3] J. Yamauchi, Y. Ubara, K. Ikeda, and K. Takaichi, “Retroperitoneal liposarcoma with lamellar bone inside,” The Lancet, vol. 377, no. 9769, p. 941, 2011.
[4] W. Sun, X. Sun, and D. Cao, “Dedifferentiated liposarcoma of the retroperitoneum with osteosarcomatous component,” Clinics and Practice, vol. 2, no. 2, 2012.
[5] K. Hatanaka, T. Yoshioka, T. Tasaki, and A. Tanimoto, “Paratesticular dedifferentiated liposarcoma with leiomyosarcomatous differentiation: a case report with a review of literature,” Diagnostic Pathology, vol. 8, no. 1, article 142, 2013.
[6] T. Fujii, T. Arai, M. Sakon et al., “Retroperitoneal dedifferentiated liposarcoma with osteosarcomatous components: a case report,” International Journal of Clinical and Experimental Pathology, vol. 6, no. 7, pp. 1427–1431, 2013.
[7] A. P. Lietman, W. K. Barsoum, J. R. Goldblum et al., “A 20-year retrospective review of surgically treated liposarcoma at the Cleveland clinic,” Orthopedics, vol. 30, no. 3, pp. 227–234, 2007.
[8] D. McCormick, T. Mentzel, A. Beham, and C. D. M. Fletcher, “Dedifferentiated liposarcoma: clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas,” The American Journal of Surgical Pathology, vol. 18, no. 12, pp. 1213–1223, 1994.
[9] Z. A. Dotan, R. Tal, D. Golijanin et al., “Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience,” Cancer, vol. 113, no. 3, pp. 573–581, 2008.
[16] N. Pervaiz, N. Colterjohn, F. Farrokhyar, R. Tozer, A. Figueredo, and M. Ghert, “A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma,” Cancer, vol. 113, no. 3, pp. 573–581, 2008.
[17] H. S. Kim, J. Lee, S. Y. Yi et al., “Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy,” BMC Cancer, vol. 9, article 205, 2009.